Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 14/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119373 | 1.00 | ENPP2 (0.60) | ENPP2MAPTDDB1CRBNKDM4E | |
| SCHEMBL31119382 | 0.91 | ENPP2 (0.49) | ENPP2DDB1CRBNATMMKNK1 | |
| SCHEMBL30130173 | 0.91 | ENPP2 (0.49) | ENPP2DDB1CRBNATMMKNK1 | |
| SCHEMBL31119383 | 0.91 | ENPP2 (0.49) | ENPP2DDB1CRBN | |
| SCHEMBL30130329 | 0.91 | ENPP2 (0.49) | ENPP2DDB1CRBN | |
| SCHEMBL30130265 | 0.91 | ENPP2 (0.51) | ENPP2MAPTDDB1CRBN | |
| SCHEMBL31119370 | 0.90 | ENPP2 (0.49) | ENPP2DDB1CRBN | |
| SCHEMBL30130209 | 0.90 | ENPP2 (0.49) | ENPP2DDB1CRBNKDM4EMKNK1 | |
| SCHEMBL31119379 | 0.90 | ENPP2 (0.49) | ENPP2DDB1CRBNKDM4EMKNK1 | |
| SCHEMBL30130281 | 0.90 | ENPP2 (0.49) | ENPP2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327408-A1 | COMPOUNDS CONTAINING TETRAHYDRONAPHTHYRIDINONE OR TETRAHYDROPYRIDOPYRIMIDINONE SKELETON, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRCP, TMPRSS15, WEE1 | ENPP2 1245/4885MAPT 2375/4885DDB1 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.